Semaglutide News and Research

Latest Semaglutide News and Research

Cardiovascular risk score decreases after one year of semaglutide use in obese patients, study shows

New research presented at this year's European Congress on Obesity in Dublin, Ireland shows that patients treated with the obesity drug semaglutide have a decreased cardiovascular risk score after one year of use.

22 May 2023

Multicenter, 1-year-long real-world study shows effectiveness of semaglutide for weight loss

New research presented at this year's European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study.

22 May 2023

Tirzepatide improves body composition across a range of adult age groups, study shows

A new analysis of SURMOUNT-1, the first Phase 3 study of tirzepatide in adults for chronic weight management shows that tirzepatide improves body composition across a range of adult age groups.

19 May 2023

What is the association between obesity and insulin resistance in youth and its production of colon-derived acetate, gut-derived hormone secretion, and adipose tissue lipolysis?

Researchers assessed whether insulin resistance and adiposity in youth were linked to the fermentation of dietary fibers.

11 May 2023

Boosting gut health with short-chain fatty acids

Research paper provides an overview of short-chain fatty acids (SCFAs) and their role in regulating gut homeostasis. It also discusses SCFA-producing bacteria and potential therapeutic approaches to boost SCFA levels in the gut to treat related diseases.

9 May 2023

Insights from experts on the neurobiological processes involved in appetite regulation

Researchers summarized the main findings related to the neurobiological regulation of appetite presented at the 23rd Harvard Nutrition Obesity Symposium in June 2022.

8 May 2023

Study evaluates simultaneous effects of exercise and diet-induced weight reduction in patients with type 2 diabetes

Researchers performed a four-armed, 16-week randomized clinical trial on type II diabetes.

3 May 2023

Will they or won’t they (block the abortion pill)?

Supreme Court justices could act at any moment on access to the abortion pill mifepristone. Beyond reproductive health, their ruling could carry significant implications for states' rights and FDA independence and integrity.

20 Apr 2023

Experimental anti-obesity drug may control appetite without surgery or nausea

Imagine getting the benefits of gastric bypass surgery without going under the knife -; a new class of compounds could do just that. In lab animals, these potential treatments reduce weight dramatically and lower blood glucose.

29 Mar 2023

The policy, and politics, of Medicare Advantage

Medicare Advantage, the private-sector alternative to original Medicare, now enrolls nearly half of all Medicare beneficiaries.

23 Mar 2023

Childhood and adolescent obesity: time to act

In a recent review published in the journal Frontiers in Pediatrics, researchers at the Medical College of Wisconsin presented an overview of the pathophysiological mechanisms, health implications, and management options for obesity among children and adults.

21 Mar 2023

Loss of a beta cell subset might contribute to type 2 diabetes

Multiple types of beta cells produce insulin in the pancreas, helping to balance blood sugar levels. Losing a particularly productive type of beta cell may contribute to the development of diabetes, according to a new study by Weill Cornell Medicine investigators.

17 Mar 2023

The relationship between intestinal microbiome dysbiosis and atherosclerosis

Researchers investigate the impact of intestinal microbiota dysbiosis on atherosclerotic cardiovascular disease incidence.

15 Mar 2023

Long-acting GIPRA inhibits feeding and lowers body weight in mice with diet-induced obesity

The hormone glucose-dependent insulinotropic polypeptide (GIP) is considered obesogenic. In contrast, GIP receptor agonists (GIPRAs) have shown reduced feeding and body weight in an obese mouse model. Therefore, the precise effects exerted by GIP and GIPRAs remain elusive.

14 Mar 2023